Illumina (Illumina) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Illumina 5-Year EBITDA Growth Rate?

Illumina's EBITDA per Share for the three months ended in Dec. 2023 was $-0.25.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Illumina was 119.60% per year. The lowest was -4.00% per year. And the median was 27.30% per year.

Competitive Comparison of Illumina's 5-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Illumina's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Illumina's 5-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Illumina's 5-Year EBITDA Growth Rate falls into.

Illumina 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Illumina (NAS:ILMN) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Illumina 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Illumina's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (Illumina) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ILMN:Mexico 1ILMN:Italy ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Executives

Aimee L Hoyt	officer: SVP, Chief People Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen	director, officer: Chief Executive Officer	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi	officer: SVP Product Development	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno	director	C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen	officer: VP, Chief Accounting Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell	officer: Sr VP & General Counsel	5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank	officer: Chief Public Affairs Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo	officer: SVP Chief Medical Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins	officer: SVP, Chief Information Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels	officer: Chief of Global Operations	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley	officer: President & CEO	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121